144822-63-9 Usage
Uses
Used in Pharmaceutical Industry:
1-[5-O-[Bis(4-methoxyphenyl)phenylmethyl]-2-deoxy-2-fluoro-beta-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione is used as an antiviral agent for its ability to inhibit the replication of viral DNA and RNA, thereby preventing the spread of viral infections.
1-[5-O-[Bis(4-methoxyphenyl)phenylmethyl]-2-deoxy-2-fluoro-beta-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione is also used as an antitumor agent due to its capacity to interfere with the replication of tumor cells' DNA and RNA, thus hindering their growth and proliferation.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 1-[5-O-[Bis(4-methoxyphenyl)phenylmethyl]-2-deoxy-2-fluoro-beta-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione serves as a valuable compound for studying the structure-activity relationships of nucleoside analogs and their potential as therapeutic agents. Its unique structure allows researchers to explore modifications and derivatives that may enhance its antiviral and antitumor properties or uncover new applications in medicine.
Used in Drug Development:
1-[5-O-[Bis(4-methoxyphenyl)phenylmethyl]-2-deoxy-2-fluoro-beta-D-arabinofuranosyl]-2,4(1H,3H)-pyrimidinedione is utilized in drug development as a lead compound for the creation of new antiviral and antitumor medications. Its specific structure and activity provide a foundation for the design and synthesis of novel drugs that can target a wide range of viral and cancerous diseases, offering potential treatments with improved efficacy and reduced side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 144822-63-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,4,8,2 and 2 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 144822-63:
(8*1)+(7*4)+(6*4)+(5*8)+(4*2)+(3*2)+(2*6)+(1*3)=129
129 % 10 = 9
So 144822-63-9 is a valid CAS Registry Number.
InChI:InChI=1/C30H29FN2O7/c1-37-22-12-8-20(9-13-22)30(19-6-4-3-5-7-19,21-10-14-23(38-2)15-11-21)39-18-24-27(35)26(31)28(40-24)33-17-16-25(34)32-29(33)36/h3-17,24,26-28,35H,18H2,1-2H3,(H,32,34,36)/t24-,26+,27-,28?/m1/s1
144822-63-9Relevant academic research and scientific papers
Synthesis and anti-HIV activity of 2′-deoxy-2′-fluoro-4′-C-ethynyl nucleoside analogs
Wang, Qiang,Li, Yanfeng,Song, Chuanjun,Qian, Keduo,Chen, Chin-Ho,Lee, Kuo-Hsiung,Chang, Junbiao
supporting information; experimental part, p. 4053 - 4056 (2010/08/19)
Based on the favorable antiviral profiles of 4′-substituted nucleosides, novel 1-(2′-deoxy-2′-fluoro-4′-C-ethynyl-β-d-arabinofuranosyl)-uracil (1a), -thymine (1b), and -cytosine (2) analogs were synthesized. Compounds 1b and 2 exhibited potent anti-HIV-1 activity with IC50 values of 86 and 1.34 nM, respectively, without significant cytotoxicity. Compound 2 was 35-fold more potent than AZT against wild-type virus, and also retained nanomolar antiviral activity against resistant strains, NL4-3 (K101E) and RTMDR. Thus, 2 merits further development as a novel NRTI drug.
Synthesis and anti-HCV activity of 3′,4′-oxetane nucleosides
Chang, Wonsuk,Du, Jinfa,Rachakonda, Suguna,Ross, Bruce S.,Convers-Reignier, Serge,Yau, Wei T.,Pons, Jean-Francois,Murakami, Eisuke,Bao, Haiying,Steuer, Holly Micolochick,Furman, Phillip A.,Otto, Michael J.,Sofia, Michael J.
scheme or table, p. 4539 - 4543 (2010/11/03)
Hepatitis C virus afflicts approximately 180 million people worldwide and currently there are no direct acting antiviral agents available to treat this disease. Our first generation nucleoside HCV inhibitor, RG7128 has already established proof-of-concept
